Cargando…
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing
BACKGROUND: Dolutegravir (DTG)-based antiretroviral therapy (ART) is highly effective and well-tolerated in adults and is rapidly being adopted globally. We describe the design of the ODYSSEY trial which evaluates the efficacy and safety of DTG-based ART compared with standard-of-care in children an...
Autores principales: | Moore, Cecilia L., Turkova, Anna, Mujuru, Hilda, Kekitiinwa, Adeodata, Lugemwa, Abbas, Kityo, Cissy M., Barlow-Mosha, Linda N., Cressey, Tim R., Violari, Avy, Variava, Ebrahim, Cotton, Mark F., Archary, Moherndran, Compagnucci, Alexandra, Puthanakit, Thanyawee, Behuhuma, Osee, Saϊdi, Yacine, Hakim, James, Amuge, Pauline, Atwine, Lorna, Musiime, Victor, Burger, David M., Shakeshaft, Clare, Giaquinto, Carlo, Rojo, Pablo, Gibb, Diana M., Ford, Deborah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809782/ https://www.ncbi.nlm.nih.gov/pubmed/33446115 http://dx.doi.org/10.1186/s12879-020-05672-6 |
Ejemplares similares
-
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
por: Amuge, Pauline, et al.
Publicado: (2022) -
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
por: Turkova, Anna, et al.
Publicado: (2022) -
Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial
por: Bollen, Pauline D J, et al.
Publicado: (2020) -
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial
por: Waalewijn, Hylke, et al.
Publicado: (2022) -
Breaking the unbreakable: A paediatric case of dolutegravir resistance from KwaZulu-Natal
por: Malinga, Sibongiseni, et al.
Publicado: (2023)